Cargando…

Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease

The CY2C19 and P2Y12 gene polymorphisms are responsible for resistance to clopidogrel, known as drug unresponsiveness. In this study we researched the effect of gene polymorphism on clinical results of patients who began clopidogrel therapy after acute ischemic cerebrovascular disease. The study inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sen, HM, Silan, F, Silan, C, Degirmenci, Y, Ozisik Kamaran, HI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Macedonian Science of Sciences and Arts 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413440/ https://www.ncbi.nlm.nih.gov/pubmed/25937796 http://dx.doi.org/10.2478/bjmg-2014-0072

Ejemplares similares

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults
por: Sridharan, Kannan, et al.
Publicado: (2016)

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2017)

Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel
por: Ge, Lihong, et al.
Publicado: (2019)

Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease
por: Lee, Jun-Beom, et al.
Publicado: (2011)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention
por: Liu, Guohua, et al.
Publicado: (2020)

Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China
por: Chang, Rong, et al.
Publicado: (2022)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
por: Shawky, Ahmed, et al.
Publicado: (2023)

The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
por: Meman A, Al, et al.
Publicado: (2014)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
por: Li, Changqing, et al.
Publicado: (2021)

The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease
por: Li, Xin-Gang, et al.
Publicado: (2016)

Baseline P2Y12 reactivity, kidney function, and CYP2C19 genotype determine clopidogrel responsiveness in acute stroke
por: Lee, Yi-Chung, et al.
Publicado: (2023)

Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China
por: Su, Qiang, et al.
Publicado: (2019)

On the System of Diophantine Equations x (2) − 6y (2) = −5 and x = az (2) − b
por: Zhang, Silan, et al.
Publicado: (2014)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
por: Pettersen, Alf-Aage R, et al.
Publicado: (2011)

CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
por: Sukasem, Chonlaphat, et al.
Publicado: (2013)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
por: Marchini, J.F.M., et al.
Publicado: (2017)

Correlation P2Y12 Genetic Polymorphism As Risk Factor of Clopidogrel Resistance in Indonesian Stroke Patients
por: Hidayat, Rakhmad, et al.
Publicado: (2023)

Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism
por: Afzal, Ashwad, et al.
Publicado: (2016)

Efficacy and safety of CYP2C19 genotype in stroke or transient ischemic attack patients treated with clopidogrel monotherapy or clopidogrel plus aspirin: Protocol for a systemic review and meta-analysis
por: Yao, Jia-Chen, et al.
Publicado: (2018)

Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia
por: Zhu, Wen-Yao, et al.
Publicado: (2016)

Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients
por: Zhang, Min, et al.
Publicado: (2020)

CYP2C19 polymorphisms and lipoproteins associated with clopidogrel resistance in children with Kawasaki disease in China: A prospective study
por: Zhang, Mingming, et al.
Publicado: (2022)

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
por: Zhang, Yan-Jiao, et al.
Publicado: (2022)

Application of Genomic SSR Locus Polymorphisms on the Identification and Classification of Chrysanthemum Cultivars in China
por: Zhang, Yuan, et al.
Publicado: (2014)

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020)

The impact of CYP2C19 *2 and *3 polymorphism on clopidogrel response following coronary stenting in Saudi patients with acute coronary syndrome
por: H, Khalaf, et al.
Publicado: (2014)

ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
por: Nassar, Suheir, et al.
Publicado: (2014)

Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study
por: Muller, Clotilde, et al.
Publicado: (2016)

Prevalence of Aspirin and Clopidogrel Resistance in Patients with Recurrent Ischaemic Cerebrovascular Disease
por: Karunawan, Niyata Hananta, et al.
Publicado: (2021)

Correlation study of CYP2C19 gene polymorphism and clopidogrel resistance in Han Chinese patients with cerebral infarction in Guizhou region
por: Shi, Guo-Xian, et al.
Publicado: (2021)

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China
por: Mo, Yijun, et al.
Publicado: (2023)

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant
por: Mehta, Meha P., et al.
Publicado: (2023)

Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
por: Mouhrach, Ismail, et al.
Publicado: (2023)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
por: Mirabbasi, Seyed abbas, et al.
Publicado: (2017)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
por: Kisor, David F, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ps2kqopvqb82tpdcum9lr9lr70